A detailed history of First Washington Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, First Washington Corp holds 59,117 shares of VKTX stock, worth $2.01 Million. This represents 1.58% of its overall portfolio holdings.

Number of Shares
59,117
Previous 39,690 48.95%
Holding current value
$2.01 Million
Previous $2.1 Million 77.94%
% of portfolio
1.58%
Previous 0.82%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $968,241 - $1.37 Million
19,427 Added 48.95%
59,117 $3.74 Million
Q2 2024

Aug 12, 2024

BUY
$47.39 - $80.2 $1.43 Million - $2.42 Million
30,152 Added 316.12%
39,690 $2.1 Million
Q1 2024

May 13, 2024

SELL
$17.4 - $94.5 $4 Million - $21.7 Million
-229,772 Reduced 96.01%
9,538 $782,000
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $2.21 Million - $4.7 Million
239,310 New
239,310 $4.45 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $2.6B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track First Washington Corp Portfolio

Follow First Washington Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Washington Corp, based on Form 13F filings with the SEC.

News

Stay updated on First Washington Corp with notifications on news.